IFRS require that the year-end share price of Nyrstar be used as the benchmark for the impairment in Umicore's books. Nyrstar's own detailed impairment review, which is based on expected future cash flows of the company, values Nyrstar at a significantly higher level. Umicore is not considering the sale of its stake in Nyrstar at the current share price levels.
Impairment of Umicore's stake in Nyrstar
IFRS require that the year-end share price of Nyrstar be used as the benchmark for the impairment in Umicore's books. Nyrstar's own detailed impairment review, which is based on expected future cash flows of the company, values Nyrstar at a significantly higher level. Umicore is not considering the sale of its stake in Nyrstar at the current share price levels.